ProMetic gets $4.6M Octapharma order
PrioClear prion capture resin is used in plasma product production.
LAVAL, Que.: ProMetic Life Sciences Inc. has received a $4.6-million purchase order under its supply agreement with Octapharma, a Swiss-based global plasma fractionation company that specializes in human proteins.
Shipments to Octapharma for the order are expected to exceed $2 million in the second half of 2012, ProMetic said.
“This larger than originally anticipated purchase order from Octapharma for the second half of 2012 demonstrates the industry’s growing demand for safer and differentiating plasma derived products,” ProMetic president and CEO Pierre Laurin said.
The order relates to the purchase of PrioClear, ProMetic’s proprietary prion capture resin used in Octapharma’s manufacturing process for its plasma product, Octaplas. Octaplas is currently approved for marketing in several European countries and is awaiting regulatory approval for use in North America.
ProMetic is a biopharmaceutical company located in Laval, Que. It has research and development facilities in the UK, the US and Canada and manufacturing facilities in the UK and business development activities in the US, Europe, Asia and in the Middle East.
© 2012 The Canadian Press